相关实验视频

Updated: Jan 9, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

用免疫检查点抑制剂治疗的患者的免疫血小板缩

Rebecca Karp Leaf¹, Jodi V Mones², Tushar Shenoy³

¹Massachusetts General Hospital, Boston, Massachusetts, United States.

|December 8, 2025

概括

免疫检查点抑制剂相关的免疫血栓缺血症 (ICI-ITP) 是一种罕见的并发症,影响0.25%的患者. 由于ICI-ITP与死亡率增加有关,早期识别和管理至关重要.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

免疫检查点抑制剂 (ICI) 是革命性的癌症疗法.
免疫性血栓缩 (ITP) 是已知的ICI的免疫相关不良事件.
关于ICI-ITP发生率,风险因素和结果的综合数据有限.

研究的目的:

为了确定ICI-ITP的发病率,风险因素,临床特征,治疗和结果.
评估ICI-ITP之间的关联,其严重程度和死亡率.

主要方法:

美国29家医院 (2016-2023) 开始ICI治疗的86,467名成年患者的医疗记录的回顾性审查.
多变量后勤回归用于识别ICI-ITP的风险因素.
考克斯建模评估ICI-ITP与死亡率的关联.

主要成果:

在214名患者中发生了ICI-ITP (0.25%),中位数发生在8周.
独立的危险因素包括较低的血小板水平,ICI联合治疗,第四阶段癌症和其他与免疫相关的不良事件.
ICI-ITP与几乎增加三倍的全因死亡风险有关,特别是在严重病例中.

结论:

ICI-ITP是ICI治疗的一个罕见但显著的并发症.
这项研究提供了ICI-ITP风险因素和临床过程的首次大规模描述.
及时识别和管理ICI-ITP对于改善患者的治疗结果至关重要.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...